Head and neck tumors (HNTs) constitute a multifaceted ensemble of pathologies that
primarily involve regions such as the oral cavity, pharynx, and nasal cavity. The intricate …

Importance To date, no meta-analyses have comprehensively assessed the association of
neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer …

Lung cancer is the second-most commonly diagnosed cancer and the leading cause of
cancer death worldwide. The most common histological type is non-small-cell lung cancer …

Lung cancer is the second most common and the deadliest type of cancer worldwide.
Clinically, non‐small cell lung cancer (NSCLC) is the most common pathological type of …

Objective Considering the striking evidence revealed by immunotherapy in advanced or
metastatic bladder cancer, investigators have explored neoadjuvant immunotherapy and …

Non-small cell lung cancer (NSCLC) remains a major cause of morbidity and mortality
worldwide. One-third of NSCLC patients present with surgically resectable, non-metastatic …

The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

Lung cancer demands innovative approaches for early detection and targeted treatment. In
addressing this urgent need, exosomes play a pivotal role in revolutionizing both the early …

Background Neoadjuvant immunotherapy (nIT) is a rapidly emerging paradigm for
advanced resectable non‐small cell lung cancer (NSCLC). The objectives of this …

The use of immune checkpoint inhibitors (ICIs) has become mainstream in the treatment of
non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight …